The GSK/Pfizer HIV Venture: Another Sign of Change?
Executive Summary
Pfizer and GSK inked an innovative deal to create a jointly owned company focused on HIV therapeutics. The marriage combines GSK's marketing muscle and a stable of established products with Pfizer's newer offerings. While it's unlikely the new venture will unseat rival Gilead as the top player in the HIV market, the deal could be a cash cow for both drug makers, especially if a spin-out ensues.
You may also be interested in...
Changing Pharma's Innovation DNA
A new framework for radical change in pharma's R&D organization and decision making is required. Here's a practical approach for achieving the transformation.
Changing Pharma's Innovation DNA
A new framework for radical change in pharma's R&D organization and decision making is required. Here's a practical approach for achieving the transformation.
Pharma: Serious About Change?
Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.